InhaleRx Limited is an Australia-based healthcare company. The Company is focused on...InhaleRx Limited is an Australia-based healthcare company. The Company is focused on developing medicinal drug-device products to address unmet medical needs in the pain management and mental health sectors. It is engaged in the development of precision medicine delivered through inhalation. The Company is focused on the development of innovative inhaled therapeutics. The Company’s novel drug device combinations target the treatment of breakthrough cancer pain (BTcP) (IRX211) and panic disorder (PD)(IRX611a), with the objective of helping to improve the quality of life of BTcP and PD sufferers. IRX211 is a THC based synthetic cannabinoid derived drug (dronabinol) delivered via a pMDI in a fixed dose designed to provide rapid onset analgesia for patients suffering with acute episodic bursts of breakthrough pain. It holds an approved innovation patent and has lodged an Australian provisional patent application for the treatment of BTcP with the Australian Patent Office.More
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
ASX News
